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Ethnopharmacological Relevance. Natural products, like Flaxseed (Linum usitatissimum), have traditionally been used in
inﬂammatory bowel disease (IBD). It is known to contain multiple constituents which may account for its eﬀectiveness, as
IBD is a multifaceted disease. Aim of the Study. In the current study, we aimed to assess pharmacological basis for the
medicinal use of Flaxseed in IBD. Materials and Methods. Aqueous-methanolic crude extracts of Flaxseed (Fs.Cr) and
Flaxseed oil were tested against 6% acetic acid- (AA-) induced colitis in BALB/c mice. Microscopic damage parameters of the
hematoxylin and eosin-stained and periodic acid-Schiﬀ-alcian blue-stained sections of the colon were scored to be assessed.
Possible antispasmodic mechanism was studied on isolated rabbit jejunum, while antibacterial activity was assessed in vitro
for microbes implicated in IBD. Results. In AA-induced colitis, Flaxseed oil was found to be more eﬀective in reducing
mortality and colonic ulcers than Fs.Cr at 500 mg/kg dose. Fs.Cr was more eﬃcacious in increasing mucin content as
compared to oil, exhibiting slightly greater anti-inﬂammatory eﬀect (50% vs 35%) and reducing depth of lesion (55% vs
42.31%, respectively). Antispasmodic activity of Fs.Cr (0.03 and 0.1 mg/ml) was mediated by phosphodiesterase inhibitors
(PDEI, possibly PDE-4 subtype) with a resultant increase in cAMP levels. Flaxseed oil PDEI activity was mild (1 and 3 mg/
ml). Fs.Cr (0.1 and 0.3 mg/ml) was potent in exhibiting anticholinergic activity, similar to dicyclomine, whereas Flaxseed oil
showed anticholinergic eﬀect at 1 and 3 mg/ml. Flaxseed oil (9 and 14 µg/ml) was bactericidal against enteropathogenic E.coli
(EPEC), enterotoxigenic E.coli (ETEC), and enteroaggregative E.coli (EAEC), whereas Fs.Cr exhibited bactericidal eﬀect
against EPEC at 100 µg/ml. Conclusions. Results of this study, taken together with previous studies, suggest that Flaxseed
possesses anti-inﬂammatory, antibacterial, and antispasmodic action through multiple pathways and thus oﬀers promising
potential to be developed for IBD.

1. Introduction
Inﬂammatory bowel disease (IBD) is a heterogeneous disease in which multiple triggers act simultaneously. The
major maneuvering targets in IBD are immune dysregulation, barrier, and microbial defects, along with abdominal
spasms and colic as accompanying symptoms [1]. Despite
advancement in IBD therapeutics, rate of failure to attain the

remission remains high possibly due to multifactorial etiology of the disease.
Flaxseed (scientiﬁc name: Linum usitatissimum) has
traditionally been used for IBD [2, 3]. In our earlier studies,
we provided some evidence for its traditional use by showing
that the aqueous-methanolic crude extract of Flaxseed
(Fs.Cr) ameliorated the severity in mice model of colitis by
reducing mediators of inﬂammation (myeloperoxidase and
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cytokines) and inducers of oxidative stress [4]. The extract
that we studied comprised predominantly of polar components, whereas Flaxseed as a whole is a combination of
both the polar and nonpolar constituents [5]. Therefore, to
gain an insight into the holistic potential of Flaxseed in IBD,
one of the aims of the current study was to assess the eﬀect of
Flaxseed oil (nonpolar constituents) for its eﬀectiveness
against IBD model of mice and, subsequently, compare these
parameters with Fs.Cr.
Knowing that antispasmodics have an important role in
IBD therapeutics as an adjunctive therapy [1], we also aimed
to explore the precise mode of antispasmodic mechanisms of
Flaxseed (both the extract and oil) using isolated gut tissues
from experimental animals. Earlier, we have reported that
both Fs.Cr and Flaxseed oil exhibited antidiarrheal activity
with possible involvement of Ca+2 channel inhibition and
nonspeciﬁc K+ channel activation, respectively [6, 7].
However, the possibility of other potential mechanisms was
there as the inhibitory eﬀect in isolated jejunal tissues against
carbachol- (CCh, 1 μM) induced contractions was not
studied, which can help in identifying the presence of anticholinergic and/or phosphodiesterase inhibitory mechanisms [8, 9], both of which have potential for IBD
therapeutics [10, 11].
The third aim of our study was to assess the antibacterial
activity of Flaxseed against the bacteria implicated in IBD as
microbes have an important role in IBD pathogenesis [12].
Amongst them, enteropathogenic E. coli (EPEC), enterotoxigenic E.coli (ETEC), and enteroaggregative E.coli
(EAEC) are implicated in IBD as they share virulence
properties with adherent invasive E.coli (AIEC) [13], a strain
isolated from biopsies of ileal Crohn’s disease (CD) patients.
Flaxseed has not been studied for its activity against these
pathogens. Hence, in the current study, eﬃcacy and potency
of Fs.Cr and Flaxseed oil against EPEC, ETEC, and EAEC
were tested in vitro.
To sum up, our objective in the current study is to assess
the holistic potential of Flaxseed by examining and comparing both the extract and the oil for their protective eﬀect
against acetic acid (AA)-induced colitis in mice, antispasmodic mechanisms, and antibacterial activity, thus
encompassing the diﬀerent triggers of IBD.

2. Materials and Methods
2.1. Standard Drugs. Acetic acid, acetylcholine chloride,
carbamoyl choline chloride, DPX, periodic acid, prednisolone, Schiﬀ reagent, and verapamil hydrochloride were
purchased from Sigma Chemicals Co, St. Louis, MO, USA.
Nutrient agar and Luria-Bertani broth powders used for
antibacterial assays were also purchased from Sigma
Chemicals. Chemicals used for making physiological salt
solutions, including potassium chloride, calcium chloride,
glucose, magnesium chloride, magnesium sulfate, potassium
chloride, sodium bicarbonate, sodium dihydrogen phosphate, EGTA, and sodium chloride, were obtained from
Merck, Darmstadt, Germany. DMSO and Tween-80 used for
solubilization were purchased from Merck, Darmstadt,
Germany, and Scharlau Chemicals, Barcelona, Spain,
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respectively. All chemicals used were of the available analytical grade. Cenogenics single strip kit was used for the
occult blood test. cAMP enzyme immunoassay kit for
multiple species was purchased from Arbor Assays, Ann
Arbor, MI, USA. The reference drugs gentamycin was
purchased from Sigma Chemicals Co, St. Louis, MO, USA.
Nutrient agar and Luria-Bertani broth powders used for
antimicrobial assays were purchased from Sigma Chemicals
and were of the available analytical grade.
2.2. Preparation of Plant Material (Flaxseed Extract and Oil).
Linum usitatissimum. L (Flaxseed) was bought from an
authentic herb supplier in the local market of Karachi,
Pakistan. The plant name and physical characteristics
matched the description when checked with http://www.
theplantlist.org. It appeared as deep brown ﬂat and oval seed
with a pointed tip and measured about 4 mm. A sample of
Flaxseed was deposited in the herbarium of the Department
of Biological and Biomedical Sciences of the Aga Khan
University, with a voucher number LU-SE-0812-106. The
seeds were made free of dirt and other adulterants and were
grounded ﬁnely into powder by an electrical chopper.
The aqueous-methanolic crude extract of Flaxseed
(Fs.Cr) was prepared from approximately 1 kg ground
Flaxseed by the process of cold maceration using aqueous
methanol (30 : 70 v/v) as a solvent for extraction. [7]. For oil
extraction, previously deﬁned methods were used [14].
Brieﬂy, approximately 1 kg of ground Flaxseed was soaked in
petroleum ether and kept on a water bath at 45°C for 7 days
with occasional shaking. Petroleum ether was evaporated
using Rota vapor, and the oil was ﬁltered to clarity. Respective yields of the Fs.Cr and the oil were 8 and 27% w/w
with reference to dried seeds. Both the extract and the oil
were plated on nutrient agar and incubated at 37°C for
24 hrs. There was no evident growth on the plate.
2.3. Animals. The study protocol (005-Ani-BBS-13) was
approved by ECACU (Ethics Committee for Animal Care
and Use) of the Aga Khan University, which is in accordance
with the international guidelines for laboratory animal use
and care [15]. Rabbits (1–1.5 kg) of either sex and of the local
breed were used for the ex vivo study, whereas Sprague
Dawley rats (150–200 g) were used for the in vivo study.
Female BALB/c mice, 6–8 weeks old (22–30 g), were used for
the colitis study and kept in the animal house of the Aga
Khan University (Karachi), in rectangular cages
(47 × 34 × 18 cm3) with sawdust (changed every 48 hrs). All
animals were given a standard diet and maintained under
standard conditions (temperature 22–25°C, 70–75% humidity, and 12 hr light and dark cycle). Animals also had free
access to water and food ad libitum, throughout the study,
except in case of induction of colitis, where animals’ food
was withdrawn before 18 hrs and rabbits were kept on
fasting for 24 hrs before sacriﬁcing them for ex vivo study.
Mice used for colitis study were sacriﬁced by cervical
dislocation 24 hrs after induction of colitis, whereas rabbits
starved for 24 hrs were anaesthetized with thiopental sodium
(200 mg/kg, i.p.) and sacriﬁced by cervical dislocation.
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Bacterial strains used in this study included enteropathogenic E. coli (2348/69, EPEC), enterotoxigenic E. coli
(H10407, ETEC), and enteroaggregative E. coli. (042,
EAEC), grown aerobically at 37°C in Luria-Bertani broth
(LB) for 16 hrs.
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anaesthetized and administered 0.1 ml of 6% IR acetic acid
(v/v, in 0.9% saline) through feeding needle, held vertically
for 45 sec and then ﬂushed with 0.1 ml of saline. Mice were
sacriﬁced 24 hrs after the induction of colitis.
2.7. Evaluation of AA-Induced Colitis

2.4. Working Stocks. For the in vivo and ex vivo experiments,
the extract and the oil were solubilized in 10% DMSO-5%
Tween-80, and subsequent dilutions were made in distilled
water on the day of the experiment.
For determining the eﬀect against enteric pathogens, the
Fs.Cr stock was prepared as 1000 mg/ml in 50% methanol
and then centrifuged at 14,000 g for 60 min. The supernatant
was microﬁltered, and subsequently a working stock was
prepared into 1 mg/ml. From this working stock, Fs.Cr 10
and 20 μl were picked for the antimicrobial assay (assay
volume � 200 μl) to get the total concentration to be 50 μg/ml
and 100 μg/ml, respectively.
For positive control groups (100% kill), 10 μl of microbes
was suspended with 100 μg/ml of vancomycin (for Gramnegative), whereas, for negative control, 10 μl of inoculum
was suspended with the corresponding volume of the vehicle
solvent (MeOH). 12.5% methanol, corresponding to the ﬁnal
concentration of MeOH in Fs.Cr working solutions, was
used as vehicle control. At this concentration, there was no
eﬀect on bacteria kill.
Flaxseed Oil was already in the liquid form and could be
easily drawn in minutest quantities; hence, no dilution was
required. 1 ml (1000 μl) of oil corresponding to 1 mg
(1000 μg) was centrifuged at 14000 g for 60 min and subsequently microﬁltered. From this, 1.8 μl and 2.8 μl were
picked for assay (assay volume � 200 μl) that corresponded
to 9 μg/ml and 14 μg/ml, respectively (1.8 μg in 200 μl; for
1000 μl or 1 ml, 1.8/200∗ 1000 � 9 μg/ml).
2.5. Phytochemical Analysis. The aqueous-methanolic crude
(30 : 70) extract of Flaxseed (Fs.Cr) was qualitatively analyzed according to standard methods for the presence or
absence of alkaloids, anthraquinones, coumarins, ﬂavonoids, saponins, sterols, tannins, and terpenes [16].
2.6. Experimental Protocol. The study design was similar to
our previously reported study [4] with a sham control group,
diseased control (untreated), positive control (prednisolone), and treatment groups. There were 12 animals in each
group. Three treatment groups were administered 150,
300, and 500 mg/kg Fs.Cr, and another three groups were
given similar doses of Flaxseed oil intraperitoneally (i.p.) for
5 days prior to the induction of colitis. On the 6th day, all
groups except the sham control group were induced with
colitis under anaesthesia. All the groups continued to receive
the respective treatments till the last day when mice were to
be sacriﬁced.
Acetic acid- (AA-) induced colitis model by intrarectal
(IR) administration was adopted to decipher the eﬀect of
Fs.Cr and oil, as reported previously [4, 17]. Brieﬂy, BALB/c
mice fasted for 18 hrs with access to water ad libitum were

2.7.1. Mortality Rate and DAI. The numbers of mice dying
in the respective groups were compared to the total animals
present in the same group before start of the experiment, and
mortality rate was calculated as follows:
mice died in a group
mortality Rate �
x 100.
total number of mice in that group
(1)
Disease activity index (DAI) was assessed after 24 hrs,
which was the average of loss in body weight, eﬀect on stool
consistency, and type of rectal bleed [18]. The semiquantitative scoring details are elaborated in Table 1.
2.7.2. Histological Assessment. After assessing DAI, mice
were sacriﬁced by cervical dislocation, and the colon tissues,
5 cm proximal to anus, were excised and stored in neutral
buﬀered formalin for 24 hrs. Histological processing of colon
tissues was done to assess colonic damage using hematoxylin
and eosin (H and E) staining, and mucus content was
assessed by periodic acid-Schiﬀ-alcian blue (PAS-AB)
staining. For quantifying the microscopic damage of H and E
and PAS-AB, stained sections of the colon were scored in a
single blinded fashion by a histopathologist using Neurath
et al. [19] and Vilaseca score [20], whereas goblet cells were
assessed on the basis of level of the mucin staining according
to Dorofeyev et al. [21], the details of which are presented in
Supplementary Table 1.
2.8. Antispasmodic Mechanisms. Fs.Cr and Flaxseed oil were
tested for their antispasmodic mechanisms using isolated
rabbit jejunum preparations in a tissue bath assembly set-up,
for their inhibitory eﬀect against CCh- (1 μM) induced
contractions, and for their previously reported eﬀect on
spontaneous and high K+- [7] and low K+-induced contractions [6].
2.8.1. PDE Inhibitory Activity. To assess PDE inhibitory
eﬀect of test materials, isoprenaline-induced inhibitory
CRCs were constructed against CCh- (1 µM) induced sustained contractions in isolated rabbit jejunum in the absence
and presence of the Fs.Cr and Flaxseed oil, as described
previously [22]. Since the PDEI activity of Fs.Cr was stronger
as compared to oil, Fs.Cr was further studied for its inhibitory eﬀect against the subtype of PDE enzyme along with
cAMP levels in Fs.Cr tested tissues. For this purpose, a
relationship between inhibitory eﬀects of diﬀerent PDE
enzyme inhibitors was examined in the presence and absence of Fs.Cr [23, 24]. Brieﬂy, isolated rabbit jejunal tissues
were contracted by CCh (1 µM). Once these contractions
were sustained, concentration-dependent inhibitory
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Table 1: Disease activity index (DAI) scoring criteria.

Parameter
Weight loss
Stool
Bleed/occult
DAI

Scoring criteria
1–5%, 6–10%, 11–20%, > 21% � 0, 1, 2, 3
Normal, soft but still formed, very soft, diarrhoea � 0, 1, 2, 3
Normal, hemoccult positive, blood traces in stool visible, gross bleeding = 0, 1, 2, 3
(Weight loss + stool consistency + rectal bleeding)/3

responses were constructed by cumulative dosing of PDE
enzyme subtypes 3, 4, and 5 inhibitors: cilostazol, rolipram,
and zaprinast, respectively [25]. This was followed by
restabilization of the jejunal tissues, and then the same types
of concentration-dependent inhibitory responses of each of
the PDE subtypes 3, 4, and 5 inhibitors were constructed in
the presence of 0.03 mg/ml of Fs.Cr, or one of the other types
of PDE inhibitors: cilostazol (100 μM), rolipram (3 μM), and
zaprinast (100 μM) (administered before inducing CChinduced contractions). The results were interpreted based on
the potentiation of PDE inhibitor’s concentration-dependent inhibitory responses with or without pretreatment of
Fs.Cr.
To conﬁrm the PDE inhibitory eﬀect of Fs.Cr, cAMP
content of the jejunum was measured by enzyme immunoassay [26] using cAMP enzyme immunoassay kit for
multiple species (Arbor Assays DetectX, Direct cAMP Enzyme Immunoassay kit, Ann Arbor, MI, USA). For this
purpose, CCh-induced contraction of the jejunum was
inhibited with Fs.Cr in respective diﬀerent doses. Then the
jejunal tissues were snap-frozen in liquid nitrogen; subsequently homogenized with 1 ml of sample diluent for every
100 mg of tissue, on ice; kept like this for 10 min; and then
centrifuged at ≥6000 g at 4°C for 15 min. The supernatant
was collected and either analyzed immediately or stored
frozen at −80°C. Similar steps were repeated for tissues
treated with diﬀerent doses of papaverine, which served as a
positive control, and tissues without administration of any
drug and only contracted with CCh, which served as a
negative control. The cAMP content was expressed as picomole per ml.
2.8.2. Anticholinergic Activity. In order to conﬁrm the
involvement of anticholinergic mechanisms, ﬁrst control
concentration-response curves (CRCs) of Ach were
constructed in guinea pig ileum up to the maximal eﬀect,
and then these CRCs were reconstructed in the presence
of an increasing concentration of the plant material
(Fs.Cr and oil). The rightward parallel shift in the CRCs
of Ach indicated the competitive antagonism [27], while
nonparallel displacement with suppression of the maximal response conﬁrmed the nonspeciﬁc antagonism.
[28].
2.9. Antibacterial Assay. EPEC, ETEC, and EAEC were
assessed using the quantitative antibacterial assays as
previously reported [29]. At ﬁrst, optical density (OD) of
bacteria was adjusted through Luria Broth (LB) to 0.22
corresponding to approximately 106 colony forming units
(c.f.u.), followed by making a serial dilution of bacteria at

10−1–10−6 and plating them; this became the inoculum
control. Simultaneously, in other sets of tubes, 10 µl of
respective bacterial inoculum was suspended with different doses of Flaxseed oil (9 μg/ml and 14 μg/ml) and
Fs.Cr (50 and 100 µg/ml); the total assay volume was
200 µl, and LB was used as an assay buﬀer. For negative
control, 10 µl of original inoculum (OI) was suspended
with corresponding volumes of LB instead of Flaxseed oil/
Fs.Cr. Additional negative control of the corresponding
concentration of methanol (MeOH) was used for Fs.Cr, as
it was solubilized in MeOH. For positive control groups
(100% kill), 10 µl of inoculum was suspended with 100 µg/
ml gentamycin. The assay tubes were then incubated in
CO2 incubator for 2 hrs on shaking. After incubation,
microbial cultures were 10-fold serially diluted in LB
(10−1–10−6), plated on nutrient agar plates, and incubated
further at 37°C overnight, and microbial c.f.u. were
enumerated.
The eﬀect of test material was compared to the originally
incubated number of bacteria in terms of reduction in c.f.u.
in respective treatment groups. The eﬀect was considered as
bactericidal if the concentration of bacteria in the treated
groups was less than OI. The percent bactericidal eﬀects were
determined as follows:
c.f.u. in extract
 ∗100.
original inoculum

100 − 

(2)

The conclusions were drawn based on colony count as
follows:
(1) If the microbial c.f.u. was less than the c.f.u. in OI, it
was considered as a bactericidal eﬀect
(2) If the microbial c.f.u. was similar to OI or greater
than OI, it was inferred that test material has no
eﬀect
2.10. Statistical Analysis. The data expressed are means ± standard error of the mean (SEM; n: number of experiments). One-way ANOVA was applied to diﬀerentiate
the results in cyclic AMP (cAMP) assay. A probability of
p < 0.05 was considered signiﬁcant. The concentrationresponse curves (CRCs) were analyzed by nonlinear regression using the GraphPad program (GraphPad, San
Diego, CA, USA). The antibacterial analysis was determined by unpaired t-test (two-tailed) or one-way ANOVA
followed by Tukey’s posttest. All other graphing, calculations, and statistical analyses were also carried out using
GraphPad software (GraphPad, San Diego, California,
USA).
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3. Results
3.1. Phytochemistry. Preliminary phytochemical analysis of
the aqueous-methanolic crude extract of Flaxseed (Fs.Cr)
revealed the presence of tannins, ﬂavonoids, triterpenes,
alkaloids, and coumarins, whereas saponins were weak and
anthraquinones were not detected.
3.2. Evaluation of the Eﬀect on the Ulcerative Colitis Model.
The eﬀects of Flaxseed oil and Fs.Cr at the doses of 150, 300,
and 500 mg/kg were tested against AA-induced colitis.
3.2.1. Mortality Rate and DAI. The mortality rate of 6% AAinduced colitis mice (untreated) was 58%, whereas pretreatment with Flaxseed oil and extract reduced the mortality rate signiﬁcantly (p < 0.01 vs p < 0.001 at 300 and
500 mg/kg doses, respectively). The optimal eﬀect of Fs.Cr
was at 300 mg/kg dose, whereas Flaxseed oil’s optimal eﬀect
was evident at 500 mg/kg dose. The eﬀect of oil at 500 mg/kg
dose was superior to that of the extract (8.33 ± 5% vs
33 ± 6%).
Overall, both the extract and oil improved the DAI
signiﬁcantly as compared to diseased control. Fs.Cr improvement in DAI started at 150 mg/kg, whereas Flaxseed oil
improved DAI at 300 mg/kg dose. Both Flaxseed oil and
extract were eﬀective at 300 mg/kg doses, with Fs.Cr being
more eﬀective at this dose, whereas Flaxseed oil exhibited
maximum improvement in DAI at 500 mg/kg dose (Table 2).
3.2.2. Microscopic Damage. Both the extract and oil were
equally eﬃcacious in improving the microscopic damage
parameters when compared to diseased control. However,
the type of protective eﬀect was diﬀerent for both Fs.Cr and
Flaxseed oil.
Both Flaxseed oil and Fs.Cr were equally eﬃcacious in
reducing neutrophil inﬁltration (Neurath score) except that
Fs.Cr was more potent than Flaxseed oil. The colonic
damage scores showed signiﬁcant dose-dependent reduction
by Fs.Cr, with maximum reduction by 55.18% at 300 mg/kg
dose, and the oil also showed similar eﬃcacy (55.89% reduction in Neurath score) but at 500 mg/kg dose. When the
microscopic damage was quantiﬁed using Vilaseca score
[20], which is the sum of the size of ulceration, inﬂammation, and depth of lesion, Flaxseed oil was more eﬃcacious in reducing ulcers (max eﬀect: 77.5% at 500 mg/kg
dose) as compared to Fs.Cr (max eﬀect: 56% at 300 mg/kg
dose). Fs.Cr was slightly more eﬃcacious than Flaxseed oil in
reducing the inﬂammation (50% vs 35.46% respectively) and
depth of lesion (55% vs 42.31% respectively).
The eﬀects of Flaxseed extract and oil were compared for
their eﬀectiveness in increasing the mucin score, as compared to diseased control. Fs.Cr was both potent and eﬃcacious (92% mucin increase) in promoting mucin
production as compared to oil (maximum mucin production: 42.28%). The percentage diﬀerence is elaborated in
Table 3, whereas the scores are illustrated in Supplementary
Table 2.
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3.3. Antispasmodic Mechanisms. Both Fs.Cr and Flaxseed oil
were studied for their eﬀect against CCh-, high K+-, and low
K+-induced contractions in a spontaneously contracting
rabbit jejunum, to assess and conﬁrm their possible antispasmodic mechanisms.
When compared for inhibitory eﬀect against diﬀerent
spasmogens, Fs.Cr showed selectivity for CCh-induced
contractions (Figure 1(a)), exhibiting inhibitory eﬀect at
lower doses, similar to that of papaverine (Figures 1(c) and
1(d)), whereas verapamil showed higher potency against
high K+ when compared with carbachol (Figure 1(d)).
Similarly, Flaxseed oil exhibited inhibitory eﬀect against
CCh- (1 μM) induced contractions at a higher concentration
of 5 mg/ml (Figure 1(b)); hence, Fs.Cr was more potent
against CCh- (1 μM) induced contractions (p < 0.01) as
compared to Flaxseed oil. In contrast, Flaxseed oil was found
selective at the activation of K+ channels, which was absent
in Fs.Cr at the tested doses, whereas its eﬀect against high K+
was negligible as previously reported [6] (Figure 1(b)).
Any material that will inhibit CCh-induced contraction
is either PDEI, anticholinergic, or both [26]. Hence, Fs.Cr
was further explored for its anticholinergic and PDEI
mechanisms.
3.3.1. PDEI Activity of Fs.Cr and Flaxseed Oil. To test for the
presence or absence of PDEI-like eﬀect, inhibitory CRCs of
isoprenaline were constructed against CCh-induced sustained contractions (Figures 2(a)–2(d)) in the presence and
absence of Fs.Cr (Figure 2(a)) and Flaxseed oil (Figure 2(b))
in rabbit jejunal tissues. Pretreatment of the jejunal tissues
with increasing concentrations of Fs.Cr (0.01 and 0.03 mg/
ml) and Flaxseed oil (1 mg/ml and 3 mg/ml) shifted the
isoprenaline-induced inhibitory CRCs against CCh (1 μM)
to the left, indicating PDEI, similar to papaverine at 1 and
3 μM (Figure 2(c)), whereas there was no shift in the case of
verapamil (0.03 and 0.1 μM) (Figure 2(d)). Due to the strong
PDEI eﬀect of Fs.Cr, it was further explored for in-depth
mechanisms for its subtype and the associated increase in
cAMP levels.
Since PDE inhibitory eﬀect was the predominant
mechanism for the antispasmodic activity of Fs.Cr, it was
further studied for the possible subtype of PDE involved.
PDEI are expected to inhibit CCh-induced sustained contractions. Hence, at ﬁrst, the eﬀect of diﬀerent PDE inhibitors’ subtypes against CCh-induced contraction, with
and without pretreatment with Fs.Cr, was recorded
(Figures 3(a)–3(c)).
Cilostazol, a selective inhibitor of PDE-3, showed a
concentration-dependent inhibitory response against CChinduced contraction as evident in Figures 3(a). Pretreatment
with Fs.Cr potentiated the inhibitory eﬀect of cilostazol
(p < 0.001), as evident by a leftward shift in the curve along
with a signiﬁcant reduction in EC50 values (additive eﬀect)
(Table 4). A similar pattern was evident when eﬀect of
cilostazol was measured with preincubation of rolipram
(PDE-4 subtype inhibitor) and zaprinast (PDE-5 subtype
inhibitor) indicating that Fs.Cr may have inhibited a PDE
subtype other than cilostazol. A similar leftward shift was
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Table 2: Comparison of mortality rate and DAI of acetic acid-induced colitis in mice.

Untreated
150 mg/kg
300 mg/kg
500 mg/kg

Mortality rate (%)
Oil
Extract
58.33 ± 4.23#
50 ± 5.01%
55 ± 12%
33.33 ± 5%∗
33.33 ± 6%∗∗
25 ± 8%∗∗
∗∗∗
8.33 ± 5%
33 ± 6%∗∗∗

DAI (%)
Oil
2.17 ± 0.06
2.1 ± 0.08
1.80 ± 0.02∗∗
0.93 ± 0.01∗∗∗

Extract
2.11 ± 0.03#
1.17 ± 0.01∗
0.71 ± 0.21∗∗
0.97 ± 0.23∗∗

Values given are means ± SEM of 3 experiments (n � 12). One-way ANOVA was used for statistical analysis followed by Tukey’s posttest. ∗ p < 0.05, ∗∗ p < 0.01;
∗∗∗
p < 0.001 compared with the untreated group (#); all the drugs were administered intraperitoneally for 7 days. Colitis was induced on the 6th day with
intrarectal administration of 0.1 ml 6% acetic acid. Mice were assessed 24 hrs after induction of colitis. DAI [18] � (weight loss + stool consistency + rectal
bleeding)/3; mortality rate � (mice died in a group/total number of mice in that group) × 100. DAI: disease activity index.

Table 3: Comparison of histopathological scoring for Flaxseed oil and extract.
Oil % reduction from control
Untreated
150 mg/kg
300 mg/kg
500 mg/kg

Extract % reduction from control
Ulceration

3.13%
25%
77.5%∗∗

24%
56%∗
33.14%

Oil vs. extract

∗∗∗
∗∗∗
∗∗∗

Inﬂammation
Vilaseca score

Neurath score
Mucin score (%)

150 mg/kg
300 mg/kg
500 mg/kg

2.27%
13.64%
35.46%∗∗

150 mg/kg
300 mg/kg
500 mg/kg
150 mg/kg
300 mg/kg
500 mg/kg
150 mg/kg
300 mg/kg
500 mg/kg

7.69%
23.08%∗∗
42.31%∗∗∗
8.82%
26.47%∗∗
55.89%∗∗∗
2.85%
35.71%∗
42.28%∗∗

Depth of lesion1

8.5%
50%∗∗∗
30%
23.07%∗
55%∗∗∗
38.47%∗∗∗
33.04%
55.18%∗
51.15%∗∗
25%
75%∗∗∗
91.66%∗∗∗

∗∗∗
∗∗∗

NS
∗∗∗

NS
∗∗
∗∗∗

NS
∗∗∗
∗∗∗
∗∗∗

Neurath score [19]: score 0 � no leukocyte inﬁltration; score 1 � low level of leukocyte inﬁltration; score 2 � moderate level of leukocyte inﬁltration; score
3 � moderate level of leukocyte inﬁltration, high vascular density, and thickening of colon wall; score 4 � transmural leukocyte inﬁltration, loss of goblet cells,
high vascular density, and thickening of the colon wall. Vilaseca Score [20]: total score � 9 ulceration: 1 [no ulcer, epithelialization; small ulcers < 3 mm; large
ulcers ≥ 3 mm � score 0, 1, 2, respectively]; inﬂammation: 3 [none, mild, moderate, severe; 0, 1, 2, 3]; depth of lesion: 3 [none, mucosa, muscularis propria,
serosa; 0, 1, 2, 3]; mucin score [21]: score 4 [<1% of stained cells; 1–30% of stained cells (low level of staining); 30–80% of stained cells (medium level of
staining); up to 80% of stained cells � score 0, 1, 2, 3]. One-way ANOVA followed by Tukey’s posttest was used for analysis. Values expressed are means ± SEM
(n � 6). ∗ p < 0.05, ∗∗ � p < 0.01; ∗∗∗ � p < 0.001 vs AA. #Diseased control group. Two-way ANOVA followed by Bonferroni’s posttest was used for comparing
the eﬀect of corresponding doses of Flaxseed oil and extract. All the drugs were administered i.p. Colitis was induced by IR administration of 0.1 ml 6% acetic
acid during anaesthesia. Tissues were embedded in formalin for another 24 hrs, then processed, and stained with H and E and PAS-AB staining. i.p.:
intraperitoneally; IR: intrarectal; H and E: hematoxylin and eosin; PAS-AB: periodic acid-Schiﬀ-Alcian blue.

evident when inhibitory CRC was constructed against
zaprinast, in presence of Fs.Cr and other standard PDE
inhibitors.
Rolipram, a selective inhibitor of PDE-4, inhibited the
contraction induced by CCh in a concentration-dependent
manner. Interestingly, the inhibitory response of rolipram
was not potentiated by pretreatment with Fs.Cr, whereas it
was signiﬁcantly potentiated by pretreatment with cilostazol
(p < 0.001) and also zaprinast (p < 0.001) as evident in
Figures 3(b). Hence, it is concluded that Fs.Cr might be
inhibiting PDE-4 subtype similar to rolipram, a standard
PDE-4 inhibitor.
Since cAMP levels are increased when PDE enzyme is
inhibited in the tissues [30], we also estimated the cAMP
levels in the control CCh-treated tissues and compared

them with Fs.Cr- and papaverine-pretreated jejunal
tissues. Untreated tissues showed 16.89 ± 1.42 pmol of
cAMP/ml of tissue homogenate. Compared to this, Fs.Cr
after treatment with 1, 3, and 5 mg/ml of Fs.Cr against
CCh-induced contraction showed cAMP levels up to
29.11 ± 1.62 (p < 0.05), 65.99 ± 1 (p < 0.001), and
78.73 ± 1.17 (p < 0.001) pmol/ml, respectively, as evident
in Figure 4(a). The papaverine control showed similar
pattern of the rise in the cAMP levels with control CChtreated
tissues
showing
cAMP
levels
of
21.01 ± 1.75 pmol/ml, whereas treatment with 1 μM and
3 μM of papaverine in CCh-contracted tissues increased
the cAMP levels to 58.7 ± 4.2 pmol/ml (p < 0.05) and
91.89 ± 3.4 (p < 0.001) pmol/ml, respectively, as evident
in Figure 4(b).
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Figure 1: Inhibitory eﬀect of aqueous-methanolic crude extract of Flaxseed (Fs.Cr) (a), Flaxseed oil (b), papaverine (c), and verapamil (d)
against CCh-, high K+- (80 mM), and low K+- (25 mM) induced contractions in isolated rabbit jejunal preparations.

3.3.2. Anticholinergic Activity of Fs.Cr and Flaxseed Oil.
Besides PDEI, CCh-induced contraction is also inhibited by
anticholinergics; therefore, Flaxseed extract and oil were
further tested in rabbit jejunal tissues to see if anticholinergic
activity exists. Pretreatment of Fs.Cr (0.1 and 0.3 mg/ml)
shifted Ach-induced bolus CRCs to the right in parallel
manner without suppression of the maximal response, in a
concentration-dependent manner as shown in Figure 5(a).
With further increase in the dose of extract at 1 mg/ml, the
rightward shift in Ach CRCs was nonparallel with suppression in maximal response. Dicyclomine, which is known
to exhibit a cholinergic antagonist eﬀect at a lower dose and

CCB at a higher dose, was used as a standard and showed a
similar rightward parallel shift of Ach CRCs at 0.03 μM
(p < 0.05) and a rightward nonparallel shift due to suppression of the maximal response at 0.1 μM, as shown in
Figure 5(c).
Flaxseed oil shifted Ach-induced bolus CRCs to the right
in parallel manner without suppression of the maximal
response, at higher doses of 1, 3, and 5 mg/ml in a concentration-dependent manner as shown in Figure 5(b),
similar to atropine, as shown in Figure 5(d). This further
indicates that Fs.Cr was more potent anticholinergic than
Flaxseed oil.
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Figure 2: Concentration-response curves (CRCs) of isoprenaline.

3.4. Antibacterial Activity. Both Flaxseed extract (Fs.Cr)
and oil were tested in vitro for their eﬀect against EPEC,
ETEC, and EAEC. Flaxseed oil was more potent and efﬁcacious against all the tested bacteria, as compared to
Fs.Cr. The bactericidal eﬀect of Flaxseed oil increased
dose-dependently at 9 and 14 μg/ml (Figures 6(a)–6(c)),
whereas the eﬀect of Fs.Cr was only evident against EPEC
at 100 μg/ml, and no eﬀect was observed against ETEC and
EAEC (Figures 6(d)–6(f )). The colony counts (c.f.u.) are
elaborated in Supplementary Table 3. Hence, the minimal
eﬀective dose for antibacterial activity against these
bacteria is almost 100 μg/ml for Fs.Cr and 9 μg/ml for
Flaxseed oil.

Since Fs.Cr did not exhibit bactericidal activity against
ETEC and EAEC, a possibility of bacteriostatic mechanism
was tested by increasing the incubation time from 2 to 16 hrs
(to provide time for bacteria to grow). Doses of 5 and
12.5 mg/ml of Fs.Cr were used for assay time of 16 hrs,
whereas doses of 0.05 and 0.1 mg (50 and 100 µg/ml) of Fs.Cr
were used when assay time was 2 hrs. The analysis is shown
in Supplementary Figures 2–4 (A-B).

4. Discussion
Inﬂammatory bowel disease (IBD) is a manifestation of
multiple dysregulations acting simultaneously; therefore, it
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Figure 3: ((a)–(c)) Eﬀect of Fs.Cr on the relaxant responses of cilostazol (a), zaprinast (b), and rolipram (c) in rabbit jejunum precontracted
with CCh (1 μM).

Table 4: EC50 values of diﬀerent PDE-subtype inhibitors with and without Fs.Cr pretreatment.
PDE inhibitor
Cilostazol (µM)
EC50
CI
Rolipram (µM)
EC50
CI
Zaprinast (µM)
EC50
CI

Control
156.3#
76.32 to 319.9
Control
12.41#
6.42 to 23.98
Control
146.3#
74.45 to 287.4

+Fs.Cr
0.91∗∗∗
0.35 to 2.35
+Fs.Cr
10.34
5.49 to 19.46
+Fs.Cr
3.59∗∗∗
1.381 to 9.37

+Rolipram
0.15∗∗∗
0.06 to 0.39
+Cilostazol (µM)
2.421∗∗∗
1.21 to 4.83
+Rolipram
19.28∗∗∗
11.91 to 31.21

+Zaprinast
2.83∗∗∗
1.48 to 5.41
+Zaprinast
1.61∗∗∗
0.96 to 2.70
+Cilostazol
0.38∗∗
0.15 to 0.96

EC50: eﬀective concentration to produce 50% response; CI: conﬁdence interval; Fs.Cr: aqueous-methanolic crude extract of Flaxseed (70; 30). All concentrations are in µM. ∗∗∗ p < 0.001; ∗∗ p < 0.01; one-way ANOVA was done followed by Tukey’s posttest to compare the signiﬁcance of means ± SEM of
controls with other groups. #All treatment groups are compared with Control.
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Figure 4: Eﬀect of Fs.Cr (a) and papaverine (b) on the cyclic nucleotide content of rabbit jejunum.
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Figure 5: Concentration-response curves of Ach in the absence and presence of the increasing concentrations of (a) Fs.Cr, FS oil (b),
dicyclomine (c), atropine (d), and verapamil (e) in isolated rabbit jejunum preparations.

needs to be catered from diﬀerent ends for an eﬀective
disease control. Multitargeted approach has gained a lot of
interest in IBD therapeutics [1]; therefore, we explored the
various pharmacological targets of Flaxseed in order to
rationalize its medicinal use in IBD.
Our preliminary studies have shown that Flaxseed extract (Fs.Cr) was eﬀective against 6% AA-induced colitis in
mice due to its antioxidant and anti-inﬂammatory activities
[4]. However, this does not represent the potential of whole
Flaxseed, as the extract, so prepared, mainly constitutes
polar compounds of Flaxseed [5]. Hence, we studied different mechanisms of both Flaxseed extract (known to

contain polar constituents) and oil (known to contain
nonpolar constituents) and then compared their eﬀects on
various parameters implicated in IBD.
The ﬁrst step was to identify the eﬀectiveness of Flaxseed
oil against IBD and compare it with Flaxseed extract (Fs.Cr).
It was evident with parameters such as mortality rate, disease
activity index (DAI), and microscopic scoring that Flaxseed
oil was as eﬀective in ameliorating the severity of IBD in
mice model as Fs.Cr; however, there were some diﬀerences.
One of the diﬀerences was that Fs.Cr was more potent than
Flaxseed oil in producing these eﬀects. Flaxseed oil was more
eﬃcacious in reducing ulcer size as compared to Fs.Cr
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Figure 6: Bar charts show colony counts of ∼106 EPEC (a, d); ETEC (b, e); and EAEC (c, f ) incubated with and without Flaxseed oil (a–c)
and Flaxseed extract (Fs.Cr) (d–f ).
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reduction in neutrophil, and lymphocytic inﬁltration was
slightly better with Fs.Cr than Flaxseed oil. Fs.Cr was also
more potent and eﬃcacious in promoting mucin production
than Flaxseed oil. Despite these advancements, the mortality
rate of Flaxseed oil was less as compared to Fs.Cr Diﬀerences
in inﬂammatory and mucosal protective parameters in the
extract and oil indicate that both the polar and nonpolar
fractions of Flaxseed have the potential to mediate mucosal
protective eﬀect in the IBD model of mice and may provide a
synergistic eﬀect when given as a whole seed. This seems true
as Flaxseed and its oil showed clinical improvement in ulcerative colitis patients in one of the latest reported studies
[31]. On the contrary, our current ﬁndings are in contrast to
an earlier report, where 10% Flaxseed diet aggravated the
severity of dextran sodium sulfate- (DSS-) induced colitis
model of mice [32]. One of the possibilities for this could be
that Flaxseed meal has a laxative eﬀect [33], which is known
to aggravate colitis. Nevertheless, improvement in clinical
studies in UC patients shows that this may not be the case, or
this aspect may vary depending on the severity of the disease.
In the clinical study, patients who were not on corticosteroids and/or immune modulators were opted for, which
means that the recruited UC patients have limited disease
severity. More animal and clinical studies are needed to
clarify this aspect.
The other part of our study aimed to identify the
mechanisms of Flaxseed in terms of its antispasmodic eﬀect.
Interestingly, not only did we ﬁnd the antispasmodic
mechanisms, but we also got some lead for its anti-inﬂammatory eﬀect. We found that both Fs.Cr and Flaxseed
oil caused complete inhibition of CCh-induced contraction,
compared with other spasmogens, which is indicative of
PDE inhibitory activity and/or anticholinergic activity
[26, 34]. Upon further experimentation, it was evident that
Fs.Cr not only exhibited a stronger PDEI, but also increased
the tissue cAMP levels. Hence, we further aimed to identify
which subtype of PDEI receptor was inhibited. It was found
that Fs.Cr mediated the similar inhibitory pathway for PDE
enzyme as rolipram, a standard PDE4 inhibitor. This was
identiﬁed because Fs.Cr and rolipram given simultaneously
could not produce synergistic inhibitory eﬀect against CChinduced contraction, whereas other PDEI, when coadministered with Fs.Cr, potentiated the eﬀect, indicating that
perhaps rolipram and Fs.Cr worked through the same
subtype of PDE enzyme. This interpretation is further
supported by previous studies where the eﬀect of one of the
subtypes of PDE inhibitors has been potentiated against
CCh-induced contraction when pretreated with the other
subtypes of PDE inhibitor [23, 24, 30]. This ﬁnding has a
very important implication because blocking PDE-4 enzyme
has been proposed as one of the novel approaches to target
IBD. PDE-4 enzymes are present on inﬂammatory cells, and
their inhibition prevents mucosal damage and subsequent
inﬂammatory cell inﬁltration by increasing cAMP [35]. Our
ﬁndings are also relatable because subsequently we were able
to show the increased level of cAMP in the Fs.Cr-treated
tissues, which is the end result of PDE-4 subtype inhibition.
Interestingly, in the HPLC ﬁngerprints of Fs.Cr (unpublished), one of the peaks matched quercetin, a ﬂavonoid that
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has lately been identiﬁed as a potential PDE-4 inhibitor [36],
and has been shown to ameliorate the severity of acetic acid
colitis in rats [37].
Fs.Cr was the most potent against CCh-induced contraction, resembling papaverine. It was however diﬀerent in
that it showed some selectivity against high K+, like
dicyclomine, whereas papaverine showed similar inhibition against both spontaneous and high K+-induced contractions. This raised the possibility of an additional
anticholinergic along with Ca+2 antagonist-like activity,
similar to dicyclomine component at a higher dose. Interestingly, when tested for its anticholinergic activity,
Fs.Cr, at 0.3 and 1 mg/ml concentrations, caused the
rightward shift of the CRCs of Ach without suppression of
the maximum response, a classic pattern of a competitive
antagonist [27] such as dicyclomine. Expectedly, at the
higher concentration of 3 mg/ml, Fs.Cr further shifted the
CRCs of Ach to the right but suppressed the maximal
response, possibly due to the Ca+ channel antagonist-like
mechanism, which has also been reported earlier [7].
Hence, Fs.Cr has been proved to exhibit multiple antispasmodic mechanisms ranging from PDEI-like eﬀect at a
lower concentration, followed by anticholinergic at a relatively higher concentration and Ca+ antagonist-like eﬀect
at a further higher concentration. Contrary to the extract,
Flaxseed oil mediated antispasmodic eﬀect predominately
through K+ channel opener (KCO) activity [6]. Both PDEI
and anticholinergic activity were evident in oil at a relatively higher concentration, whereas CCB activity could
not be observed. However, the possibility of some additional mechanisms cannot be ruled out.
With current ﬁndings, Flaxseed as a whole mediates
antispasmodic action through multiple mechanisms including PDEI (subtype PDE-4), anticholinergic, KCO, and
Ca+2 antagonist-like activities. All of these mechanisms are
known to have a protective role in IBD [10, 11, 13] and thus
provide an additional pharmacological basis for the eﬀectiveness of Flaxseed’s protective eﬀect in IBD.
Besides therapeutic use of antispasmodics in IBD, antibacterials also are used as an adjunct because reducing the
aggressive microbial load has shown improvement in clinical
outcomes in patients with IBD [38, 39]. Therefore, in the
current study, we targeted a few of the E. coli strains implicated in IBD. Flaxseed oil showed a bactericidal activity
against all the three strains tested, but Fs.Cr was bactericidal
against EPEC. This diﬀerence in eﬃcacy and potency indicates that Flaxseed oil may have a diﬀerent antibacterial
mechanism or additional chemical constituent(s) with antibacterial activity.
The bactericidal eﬀect of both Fs.Cr and Flaxseed oil
against EPEC is a very important ﬁnding because EPEC’s
invasive level is more or less similar to AIEC strain (LF82)
[13]. Moreover, EPEC has also been shown to sustain
iodoacetamide-induced UC-like colitis in rats [40]. Hence,
Flaxseed may reduce the invasive ability of E.coli in IBD
patients and possibly its consequent manifestation that
includes upregulation of NF-kβ [41], modulation of IL-1β,
IL-6, TNF-α, COX-2, and apoptosis, hence reducing inﬂammatory cascades. This eﬀect coupled with the earlier
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reported antibacterial activity of Fs.Cr against Salmonella
typhi [7], which is implicated in UC [39], and other Grampositive and Gram-negative organisms [7, 42] provides
another pharmacological basis for medicinal use of Flaxseed
in IBD. This eﬀectiveness of Fs.Cr could be correlated with
the resemblance of HPLC peaks of Fs.Cr with two synthetic
compounds that we have identiﬁed in one of our unpublished reports. Those compounds are oﬂoxacin and metronidazole, both of which have broad-spectrum coverage
against aerobic and anaerobic pathogens [43]. However, the
presence of some novel compounds is speculated based on
100% kill of VRE, which is resistant to conventional antibiotics. On the other hand, Flaxseed oil used in the current
study exhibited a peak at later retention times (supplementary Figure 1), indicating the presence of polar constituents when analyzed through HPLC. This peak may
correspond to alpha linolenic acid (ALA), as identiﬁed in
previous reports [44], that has also exhibited eﬀectiveness in
the colitis model of mice [45]. Future studies will be directed
toward the conﬁrmation of these active constituents and
their contribution to ameliorating eﬀects in IBD.
This study is the ﬁrst report on the eﬀect of Flaxseed on
bacteria implicated in IBD. Earlier, antibacterial eﬀect of
Flaxseed oil has been shown against E.coli [42], which is a
nonpathogenic strain and hence cannot be compared. The
current study shows that Flaxseed has bactericidal eﬀect
against pathogens implicated in IBD, which may contribute
to managing immune dysregulation from a diﬀerent end
than cytokine modulation.

5. Conclusion
Based on the current ﬁndings, we understand that both
Flaxseed oil and extract are eﬀective against IBD model of
mice, with possibly diﬀerent mucosal protective mechanisms. Both the extract and the oil exhibit antispasmodic
activity with partly similar mechanisms. Fs.Cr has predominant PDE inhibitor-like eﬀect and weaker Ca++ antagonist eﬀect, whereas Flaxseed oil has predominant KCOlike eﬀect and weak PDEI eﬀect. Both the extract and the oil
are eﬀective against microbes implicated in IBD, with a
stronger antibacterial activity in Flaxseed oil. This, coupled
with previously reported cytokine modulatory and antioxidant eﬀects of Fs.Cr, indicates that the whole seed must
encompass the potential of both the extract and the oil and
therefore shall give an augmented response in IBD. Hence,
Flaxseed may become a choice of remedy that helps to cater
the basic pathophysiological tenets of IBD, which involve
immune dysregulation and barrier defects as well as microbial dysregulation.
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Potassium channel opener
Hr(s):
Hour(s)
IBD:
Inﬂammatory bowel disease
IL-1β:
Interleukin-1 beta
IL-6:
Interleukin-6
i.p.:
Intraperitoneally
IR:
Intrarectal
Kg:
Kilogram
LB:
Luria-Bertani broth
MeOH: Methanolic
mL:
Milliliter
mM:
Millimolar
NF-kβ: Nuclear factor kappa-beta
OD:
Optical density
OI:
Original inoculum
PASPeriodic acid-Schiﬀ-Alcian blue
AB:
PDE-4: Phosphodiesterase-4 subtype
PDEI:
Phosphodiesterase inhibitors
Sec:
Second
SEM:
Standard error of mean
TNF-α: Tumour necrosis factor-alpha
UC:
Ulcerative colitis
v/v:
Volume/volume
w/w:
Weight by weight.
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